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We compared prevalence of hospitalization, endotra-
cheal intubation, and death among case-patients with and 
without Down syndrome during pandemic (H1N1) 2009 in 
Mexico. Likelihoods of hospitalization, intubation, and death 
were 16-fold, 8-fold, and 335-fold greater, respectively, for 
patients with Down syndrome. Vaccination and early antiviral 
drug treatment are recommended during such epidemics.
D
own syndrome is the most common chromosomal 
abnormality in persons worldwide; prevalence is 
≈1/1,000 live births (1). It is characterized by a variety of 
dysmorphic features, congenital malformations, and other 
health problems. Several risk factors for inﬂ  uenza also oc-
cur in Down syndrome patients (2): congenital heart dis-
ease in one half of patients (3), childhood obesity or excess 
weight in the majority (4), and a 8× higher prevalence of 
type 1 diabetes than in an age-matched control population 
(5). In addition, speciﬁ  c alterations in immune response 
are frequently present, including leukopenia, chemotactic 
defects (6), decreased immunoglobulin G4 levels (7), and 
T- and B-cell abnormalities (7,8) with reduced B lympho-
cytes (9). Patients with Down syndrome have an increased 
need for hospitalization because of lower respiratory tract 
disease caused by respiratory syncytial virus (10) and 
other respiratory infections (11) as well as reduced ac-
cess to healthcare (12). An increased proportion of pa-
tients with Down syndrome have pneumonia as cause of 
death (13). However, respiratory infections have not been 
associated with congenital heart disease (14). Although 
persons with Down syndrome are likely at increased risk 
for complications, these patients are not explicitly listed 
in groups that should receive priority vaccination or for 
early treatment of inﬂ  uenza. The objective of the study 
was to determine whether Down syndrome was associated 
with adverse outcomes in cases of inﬂ  uenza-like illness 
(ILI) and severe acute respiratory illness (SARI) during 
the ﬁ  rst months of the outbreak of inﬂ  uenza A pandemic 
(H1N1) 2009 virus (15).
The Study
In the ILI/SARI database of the Mexican Ministry 
of Health, we identiﬁ  ed all persons for whom Down syn-
drome (World Health Organization’s International Statisti-
cal Classiﬁ  cation of Disease and Health-related Problems, 
10th revision [ICD-10] codes Q-90.0 to Q-90.9) was cited 
among their coexisting conditions or among the causes of 
death from May 2009 through October 2009. In Mexico, 
inﬂ  uenza is a disease of mandatory notiﬁ  cation, and the da-
tabase includes all cases reported from 597 sentinel health 
units, including outpatient clinics as well as hospitals from 
all 32 states. Notiﬁ  cation includes obtaining information 
for each patient on such factors as hospitalization, antivi-
ral drug treatment, and complications, and we compared 
selected characteristics of patients with and without Down 
syndrome. ILI is deﬁ  ned as fever (>38ºC) with cough and 
headache and 1 additional respiratory or digestive symp-
tom. The deﬁ  nition of SARI adds difﬁ  culty breathing or 
acute respiratory failure to the ILI deﬁ  nition.
We also reviewed the hospital database from the Na-
tional Institute of Respiratory Diseases (INER) for associa-
tions among Down syndrome, hospitalizations, and adverse 
outcomes. INER is a national referral center for respiratory 
diseases that cares mainly for patients from metropolitan 
Mexico City who lack health insurance. For analysis, we 
included all patients with discharge diagnoses of pneumo-
nia and inﬂ  uenza (ICD-10 codes J09–J18).
We compared the prevalence of hospitalization, intu-
bation, and death among patients with Down syndrome and 
among the remaining patients. As estimators of association, 
we used odds ratios (ORs) with 95% conﬁ  dence intervals 
(CIs), and to adjust for additional variables such as age or 
sex, we used logistic regression. We also described medi-
ans and interquartile ranges (IQRs) for selected variables 
and compared age and number of coexisting conditions by 
the standard t test for independent groups.
The ILI/SARI database had 214,902 reported cases 
during the pandemic; mean patient age was 23 years (SD 
17 years); 52% of these patients were female, 83% were 
outpatients, 9% were hospitalized, and the remaining 8% 
did not have a record of hospitalization. Among the report-
ed cases, 45,772 patients had a record of coexisting condi-
tions, mainly diabetes and asthma. We found 60 (0.03%) 
patients with reported ILI/SARI who also had a diagnosis 
of Down syndrome. Patients with and without Down syn-
drome had a similar median time from onset of signs and 
symptoms to hospitalization (2 days, IQR 1–4 days), and 
the frequency of symptoms reported was similar.
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Treatment with oseltamivir was provided for most 
hospitalized patients (for 92.0% with Down syndrome and 
85.2% without Down syndrome). Persons with Down syn-
drome were younger on average than the remainder of pa-
tients (median age 8.5 years, IQR 3–26 years, vs. 20 years, 
IQR 9–34 years, respectively). In Mexico, seasonal inﬂ  u-
enza vaccination is recommended for children <3 years of 
age, but only 24% of patients with Down syndrome within 
this age range were reported to have received the vaccine, 
compared with 33% patients without Down syndrome (OR 
0.5, 95% CI 0.1–2.4, p>0.05).
According to the ILI/SARI database, patients with 
Down syndrome had an increased risk for hospitalization, 
endotracheal intubation, and death compared with patients 
without Down syndrome. Hospitalization was reported 
for 61.7 % of patients with Down syndrome compared 
with 9.2% of patients without Down syndrome (crude OR 
15.9, 95% CI 9.5–26.8; age-adjusted OR 21.2, 95% CI 
12.4–36.4). Endotracheal intubation of patients for whom 
information was available was reported for 18.2% of case-
patients with Down syndrome and 2.6% of those without 
Down syndrome (crude OR 8.2, 95% CI 3.4–19.9); 23.3% 
of those with Down syndrome died vs. 0.1% of those with-
out Down syndrome (crude OR 335, 95% CI 181–619, age-
adjusted OR 521, 95% CI, 274–991).
From January 2000 through June 25, 2009, a total of 
42,298 admissions to INER were registered; patients had a 
mean age of 42 years, (SD 23 years), and 53% of these were 
male. Fifty-nine patients had a diagnosis of Down syndrome 
(0.14%), and 12 of these had a diagnosis of pneumonia or 
inﬂ  uenza (20.3%) vs. 6.8% of the remaining population (OR 
3.5, 95% CI 1.7–6.5, p<0.05). Patients with Down syndrome 
had an increased risk for in-hospital death (age- and gender-
adjusted OR 4.6, 95% CI 2.1–9.7, p<0.05). Although pa-
tients with Down syndrome were younger (mean age 15.2 
years vs. 41.6 years, p<0.001), they were more likely to have 
a disease of the cardiovascular system (29% vs. 16%, OR 
2.1 95% CI 1.2–3.7, p = 0.01), a congenital malformation of 
the cardiovascular system (19% vs. 0.5%, OR 47, 95% CI 
24–93, p<0.001), and more coexisting conditions per patient 
(3.3 from 4 possible vs. 2.1, p<0.001). 
Conclusions
Persons with Down syndrome often manifest a vari-
ety of immune defects and several risk factors for adverse 
outcomes for pandemic (H1N1) 2009, including obesity, 
diabetes, and cardiovascular diseases. Down syndrome pa-
tients are not explicitly listed in the groups of patients at in-
creased risk for inﬂ  uenza, so early antiviral drug treatment 
and priority vaccination are prescribed for Down syndrome 
patients only if a high-risk health condition is found, for 
example, a cardiovascular disease or if persons with Down 
syndrome are considered to have a cognitive disorder (2). 
These factors may lead to inconsistent healthcare for those 
affected with Down syndrome and to missed opportunities 
for prevention and early treatment of ILI.
Patients with Down syndrome and ILI/SARI reported 
to the Mexican Ministry of Health had an increased risk for 
hospitalization, endotracheal intubation, and death. Con-
sistent with the national database, in a referral respiratory 
center, patients with Down syndrome were more likely to 
have a diagnosis of pneumonia or inﬂ  uenza and to die dur-
ing hospitalization.
The Ministry of Health database lacks detailed clinical 
information, and surveillance is based on sentinel health 
units chosen to be representative of the whole Mexican 
health system and that would provide information of good 
quality. The main risk factors for inﬂ  uenza are routinely 
requested and reported. However, the INER database in-
cludes diagnoses after hospital discharge but solely from 1 
referral hospital.  Yet both sources conﬁ  rmed an increased 
risk for hospitalization and death for patients with Down 
syndrome and ILI. Patients with Down syndrome should 
be vaccinated against the seasonal inﬂ  uenza viruses and the 
inﬂ  uenza A pandemic (H1N1) 2009 virus. Early treatment 
of Down syndrome patients for ILI should be promoted by 
health systems and Down syndrome organizations.
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